BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20809122)

  • 1. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
    Tang CH; Parham C; Shocron E; McMahon G; Patel N
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
    Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
    Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological approach to the platinum compounds].
    Sasaki Y
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
    Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
    Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer.
    Hamilton G
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1381-90. PubMed ID: 23829480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
    Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
    Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
    Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
    Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
    Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
    Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
    Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
    Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines.
    Kawamura-Akiyama Y; Kusaba H; Kanzawa F; Tamura T; Saijo N; Nishio K
    Lung Cancer; 2002 Oct; 38(1):43-50. PubMed ID: 12367792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
    Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
    Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.
    Perego P; Caserini C; Gatti L; Carenini N; Romanelli S; Supino R; Colangelo D; Viano I; Leone R; Spinelli S; Pezzoni G; Manzotti C; Farrell N; Zunino F
    Mol Pharmacol; 1999 Mar; 55(3):528-34. PubMed ID: 10051537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
    Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
    PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
    Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of cisplatin resistance by the 1,4-benzothiazepine derivative, JTV-519.
    Nakamura T; Koizumi F; Kaneko N; Tamura T; Chiwaki F; Koh Y; Akutagawa S; Saijo N; Nishio K
    Jpn J Cancer Res; 2001 Jun; 92(6):597-602. PubMed ID: 11429046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.